Reduction of soluble ICAM‐1 levels in nasal secretion by H1‐blockers in seasonal allergic rhinitis

ICAM‐1, a transmembrane glycoprotein promoting adhesion in immunologic and inflammatory reactions, was found to be increased on nasal epithelial cells of patients with allergic rhinitis. Loratadinae, an H1‐Mocker, was found to reduce in vitro the expression of ICAM‐1 on nasal epithelial cells. A dou...

Full description

Saved in:
Bibliographic Details
Published in:Allergy (Copenhagen) 1997-10, Vol.52 (10), p.1022-1025
Main Authors: Campbell, A., Chanal, I., Czarlewski, W., Michel, F.‐B., Bousquet, J.
Format: Article
Language:English
Subjects:
Adult
Albumins - analysis
Biological and medical sciences
Cetirizine - administration & dosage
Cetirizine - therapeutic use
Double-Blind Method
Epithelial Cells - drug effects
Epithelial Cells - metabolism
Histamine and antagonists. Allergy
Histamine H1 Antagonists - administration & dosage
Histamine H1 Antagonists - therapeutic use
Humans
ICAM‐1
Intercellular Adhesion Molecule-1 - analysis
Intercellular Adhesion Molecule-1 - drug effects
Intercellular Adhesion Molecule-1 - metabolism
Loratadine - administration & dosage
Loratadine - therapeutic use
Medical sciences
Nasal Lavage Fluid - chemistry
Nasal Mucosa - cytology
Nasal Mucosa - drug effects
Nasal Mucosa - metabolism
Pharmacology. Drug treatments
Rhinitis, Allergic, Seasonal - drug therapy
Rhinitis, Allergic, Seasonal - immunology
seasonal allergic rhinitis
Seasons
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ICAM‐1, a transmembrane glycoprotein promoting adhesion in immunologic and inflammatory reactions, was found to be increased on nasal epithelial cells of patients with allergic rhinitis. Loratadinae, an H1‐Mocker, was found to reduce in vitro the expression of ICAM‐1 on nasal epithelial cells. A double‐blind, parallel‐group study was carried out during the pollen season to compare the effect of two H1‐blockers, cetiraizine (10 mg OD) and loratadine (10 mg OD), on the release of soluble ICAM‐1 in nasal secretions. A group of untreated patients was used as a control group. sICAM‐1 was measured by enzyme immunoassay before and after 2 weeks of treatment. Symptoms were significantly decreased in the actively treated groups. sICAM‐1 levels were unchanged in the control group but were significantly reduced in the two treated groups (P
ISSN:0105-4538
1398-9995
DOI:10.1111/j.1398-9995.1997.tb02425.x